GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

PF-07293893   Click here for help

GtoPdb Ligand ID: 14198

Synonyms: example 2 [WO2024084390] | PF07293893
Compound class: Synthetic organic
Comment: PF-07293893 is an AMPKγ3 (PRKAG3) activator [1]. AMPKγ3 is a regulatory subunit of the heterotrimeric AMPK complex. It is exclusively expressed in skeletal muscle in the α2β2γ3 AMPK complex. The structure was disclosed during the First Time Disclosures session at the ACS Fall 2025 meeting [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 80.61
Molecular weight 562.95
XLogP 1.51
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C[C@@]1(CN(C2=NN(C)C=C2F)C(=O)C3=C1C(=C(N=C3)NC4CN(C4)C(=O)[C@@H]5C[C@@H]5F)F)C6=CC=CC(=C6F)Cl
Isomeric SMILES CN1C=C(F)C(=N1)N2C[C@](C)(C3=CC=CC(Cl)=C3F)C4=C(C=NC(NC5CN(C5)C(=O)[C@@H]6C[C@@H]6F)=C4F)C2=O
InChI InChI=1S/C26H23ClF4N6O2/c1-26(15-4-3-5-16(27)20(15)30)11-37(23-18(29)10-35(2)34-23)25(39)14-7-32-22(21(31)19(14)26)33-12-8-36(9-12)24(38)13-6-17(13)28/h3-5,7,10,12-13,17H,6,8-9,11H2,1-2H3,(H,32,33)/t13-,17+,26-/m1/s1
InChI Key KAVAKXWBLXYMNG-FRUQJNMISA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
PF-07293893 was designed as an orally administered therapeutic for potential clinical use in congestive heart failure, and it was progressed to clinical trials. However, information available online indicates that Pfizer are no longer developing this asset [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06413693 A STUDY TO LEARN HOW THE STUDY MEDICINE CALLED PF-07293893 AFFECTS MUSCLE BIOMARKERS OF HEALTHY ADULTS Phase 1 Interventional Pfizer
NCT06177457 A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants Phase 1 Interventional Pfizer
NCT05907395 A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults Phase 1 Interventional Pfizer